There is an intriguing anomaly in the approved product information for the new formulation. Like its predecessor, the 'new' document contains pivotal clinical data from the EUROPA trial which used the original formulation, that is, 2, 4 and 8 mg doses of perindopril erbumine. 4 However, the new document portrays the original clinical data as dosing with 2.5, 5 and 10 mg of perindopril arginine. This is factually incorrect and the current product information does not explain the dosing conversion. We cannot be absolutely certain that the clinical trial would have had the same result if a different formulation had been used.
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Letters, which may not necessarily be published in full, should be restricted to not more than 250 words. When relevant, comment on the letter is sought from the author. Due to production schedules, it is normally not possible to publish letters received in response to material appearing in a particular issue earlier than the second or third subsequent issue. Regulatory authorities need to respond to these strategies to encourage competition. The general community also needs to be better informed of this practice. Our focus must remain on access to affordable drugs for all Australians rather than prolonging patents for profit.
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